11Clinical Translation and Industrial Development of Microneedle‐based Products

Ryan F. Donnelly

School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK

11.1 Introduction

Despite the limited number of drugs deliverable across the skin, due to the formidable barrier properties of the stratum corneum, the value of the worldwide transdermal product market is predicted to increase from $32 billion to >$80 billion by 2024 [1]. The unprecedented global shift in the adoption of unhealthy lifestyles is presumed to be responsible for the high prevalence of chronic diseases, such as cancer and diabetes, which is expected to drive the clinical urgency to incorporate transdermal drug delivery systems in future treatments. Moreover, the rising geriatric population base, which is highly susceptible to developing the aforementioned chronic diseases, are expected to propel the demand for highly efficacious pharmacological drugs. The market is driven by technological advancements in transdermal drug delivery devices, which is anticipated to serve the market with future growth opportunities. These advancements include advanced, third‐generation, transdermal drug delivery technologies, including iontophoresis, ultrasound and microneedles or mechanical arrays. These technologies serve as effective transdermal drug diffusion alternatives that are capable of improving overall patient health and quality of life. For instance, the advent of matrix‐controlled transdermal drug diffusion comprising ...

Get Microneedles for Drug and Vaccine Delivery and Patient Monitoring now with O’Reilly online learning.

O’Reilly members experience live online training, plus books, videos, and digital content from 200+ publishers.